Friday, August 31, 2018
Moffitt Cancer Center Researchers Compare Chemotherapy Regimens for Best Outcomes in Invasive Bladder Cancer

Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder. Moffitt Cancer Center researchers examined data from more than 800 surgical patients with advanced bladder cancer to determine the best outcomes in terms of complete response rates or cancer control.  ..

Read More
Thursday, August 09, 2018
New Study Views Cancer Treatment as a Game to Find Strategies That Improve Patient Outcomes

Game theory can be utilized to identify potential flaws in current cancer treatment approaches and suggest new strategies to improve outcomes in patients with metastatic cancer. A new study authored by researchers from Moffitt Cancer Center and Maastricht University challenges the decades old standard of treatment for metastatic cancers in which drugs are typically administered continuously at the maximum-tolerated dose until the tumor progresses. ..

Read More
Tuesday, May 01, 2018
Florida Cancer Centers Awarded $1.36 Million to Fight Pancreatic Cancer

The Florida Department of Health's James and Esther King Biomedical Research Program has armed Moffitt Cancer Center, University of Florida Health Cancer Center - Gainesville, Sylvester Comprehensive Cancer Center at the University of Miami and numerous collaborating centers with $1.36 million to address cancer disparities and improve outcomes and care for individuals affected by pancreatic cancer. ..

Read More
Tuesday, February 27, 2018
Moffitt: FDA Approves Expanded Use of Immunotherapy Treatment for Lung Cancer Patients

The Food and Drug Administration announced the expanded approval of Imfinzi® (durvalumab), an immunotherapy treatment that is now available as a standard-of-care option for patients with stage III non-small cell lung cancer. ..

Read More
Tuesday, February 13, 2018
Moffitt: FDA Approves Expanded Use of Immunotherapy Treatment for Lung Cancer Patients

The Food and Drug Administration announced the expanded approval of Imfinzi® (durvalumab), an immunotherapy treatment that is now available as a standard-of-care option for patients with stage III non-small cell lung cancer.  ..

Read More
Thursday, February 01, 2018
Moffitt Researchers Discover New Approach to Stimulate an Immune Response Against Tumor Cells

In an article published in the January issue of Cancer Cell, the researchers describe how a new type of immunotherapy drug targeting the protein TIM-3 works to stimulate the immune system.  ..

Read More
Wednesday, January 10, 2018
Moffitt: Rare Melanoma Type Highly Responsive to Immunotherapy

Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed. ..

Read More
Friday, December 08, 2017
Moffitt Cancer Center Uses Innovative Treatment Strategy to Overcome Drug Resistance

Drug resistance has long been an impediment in cancer therapy. But Moffitt Cancer Center is hoping to change that with an innovative new therapeutic strategy called adaptive therapy.  ..

Read More
Saturday, October 28, 2017
Meet the Moffitt startup that helps doctors find the best treatments for cancer patients

A biotech startup founded by a Moffitt Cancer Center researcher and a medical business expert on his team has begun commercial development of technology that helps oncologists find the best treatments for their cancer patients.  ..

Read More
Wednesday, October 11, 2017
Moffitt Researchers Discover New Targets for Approved Cancer Drug

A team of researchers at Moffitt Cancer Center used cellular drug screening, functional proteomics and computer-based modeling to determine whether drugs with well-known targets may be repurposed for use against other biological targets.  ..

Read More